Carlsmed raises FY26 revenue guidance to $72M-$77M following strong Q1 results. The medical device company reported 58 percent revenue growth in the quarter with impressive 77 percent gross margins. The guidance increase reflects confidence in its aprevo lumbar system, bolstered by CMS proposals for new MS-DRGs that could expand reimbursement coverage. This regulatory development addresses a key catalyst for the company's growth trajectory. Investors should monitor CMS finalization of these codes, which could meaningfully impact adoption rates and market penetration for the platform. The combination of strong operational execution and favorable regulatory tailwinds positions Carlsmed for accelerated growth through 2026.
Post from MarketNews_en
Log in to interact with content.